These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24858311)

  • 1. Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin.
    Peng T; Wu JR; Tong LJ; Li MY; Chen F; Leng YX; Qu R; Han K; Su Y; Chen Y; Duan WH; Xie H; Ding J
    Acta Pharmacol Sin; 2014 Jul; 35(7):916-28. PubMed ID: 24858311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
    Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
    Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel amide derivatives against VEGFR-2/tubulin with potent antitumor and antiangiogenic activity.
    Liu Z; Mao S; Li H; Liu W; Tao J; Lu Y; Dong H; Zhang J; Song C; Duan Y; Yao Y
    Bioorg Chem; 2024 Oct; 151():107679. PubMed ID: 39094510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule.
    Liu ZL; Tian W; Wang Y; Kuang S; Luo XM; Yu Q
    Acta Pharmacol Sin; 2012 Feb; 33(2):261-70. PubMed ID: 22301862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
    Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
    Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.
    Ezelarab HAA; Ali TFS; Abbas SH; Sayed AM; Beshr EAM; Hassan HA
    Mol Divers; 2024 Apr; 28(2):563-580. PubMed ID: 36790582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.
    Yang M; Su Y; Wang Z; Du D; Wei S; Liao Z; Zhang Q; Zhao L; Zhang X; Han L; Jiang J; Zhan M; Sun L; Yuan S; Zhou Z
    Biochem Pharmacol; 2021 Aug; 190():114641. PubMed ID: 34077738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazoline derivatives as tubulin polymerization inhibitors with one hit for Vascular Endothelial Growth Factor Receptor 2 inhibition.
    Yang B; Zhou J; Wang F; Hu XW; Shi Y
    Bioorg Chem; 2021 Sep; 114():105134. PubMed ID: 34246970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.
    Li MY; Lv YC; Tong LJ; Peng T; Qu R; Zhang T; Sun YM; Chen Y; Wei LX; Geng MY; Duan WH; Xie H; Ding J
    Acta Pharmacol Sin; 2016 Mar; 37(3):398-407. PubMed ID: 26806300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel benzo[c]acridine-diones as potential anticancer agents and tubulin polymerization inhibitors.
    Behbahani FS; Tabeshpour J; Mirzaei S; Golmakaniyoon S; Tayarani-Najaran Z; Ghasemi A; Ghodsi R
    Arch Pharm (Weinheim); 2019 Jun; 352(6):e1800307. PubMed ID: 31012156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
    Sun WX; Han HW; Yang MK; Wen ZL; Wang YS; Fu JY; Lu YT; Wang MY; Bao JX; Lu GH; Qi JL; Wang XM; Lin HY; Yang YH
    Bioorg Med Chem; 2019 Dec; 27(23):115153. PubMed ID: 31648877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
    Ren X; Dai M; Lin LP; Li PK; Ding J
    Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Benzo[B]Furans with Anti-Microtubule Activity Upregulate Expression of Apoptotic Genes and Arrest Leukemia Cells in G2/M Phase.
    Królewska-Golińska K; Cieślak MJ; Sobczak M; Dolot R; Radzikowska-Cieciura E; Napiórkowska M; Wybrańska I; Nawrot B
    Anticancer Agents Med Chem; 2019; 19(3):375-388. PubMed ID: 30465514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.
    Wang N; Wang ZY; Mo SL; Loo TY; Wang DM; Luo HB; Yang DP; Chen YL; Shen JG; Chen JP
    Breast Cancer Res Treat; 2012 Aug; 134(3):943-55. PubMed ID: 22350787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).
    Cai YC; Zou Y; Ye YL; Sun HY; Su QG; Wang ZX; Zeng ZL; Xian LJ
    Invest New Drugs; 2011 Apr; 29(2):300-11. PubMed ID: 20012336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deacetylisovaltratum disrupts microtubule dynamics and causes G
    Zhang D; Zhang B; Zhou LX; Zhao J; Yan YY; Li YL; Zeng JM; Wang LL; Yang B; Lin NM
    Acta Pharmacol Sin; 2016 Dec; 37(12):1597-1605. PubMed ID: 27665846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.
    Ma Q; Chen W; Chen W
    Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
    Lin HY; Han HW; Sun WX; Yang YS; Tang CY; Lu GH; Qi JL; Wang XM; Yang YH
    Eur J Med Chem; 2018 Jan; 144():137-150. PubMed ID: 29268130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.